{'fraction_non_alphanumeric': 0.025787965616045846, 'fraction_numerical': 0.008595988538681949, 'mean_word_length': 5.99, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
POPULATION PHARMACOKINETICS OF PHENYTOIN FROM ROUTINE CLINICAL DATA IN JAPAN

Routine clinical pharmacokinetic data collected from out‐patients who received phenytoin were analysed to estimate population pharmacokinetic parameters. There were 505 steady‐state phenytoin concentrations and associated dosage rates (mg/day) from 220 out‐patients. The data were analysed using NONMEM, a computer program designed for population pharmacokinetic analysis that allows pooling of data from many individuals. The influence of weight on the maximum elimination rate (Vm) and age on the Michaelis‐Menten constant (Km) or the influence of dosage form on the bioavailability (F) of phenytoin were investigated.